Cartesian Therapeutics (RNAC) Preferred Dividend Payments (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Preferred Dividend Payments for 4 consecutive years, with $2.6 million the latest figure, recorded in Q2 2025.

• In Q2 2025, Preferred Dividend Payments fell 37.55% year-over-year to $2.6 million; the TTM figure through Jun 2025 stood at $6.8 million (up 62.45% YoY), while the FY2016 annual figure was $4.6 million, down 37.75% from the prior year.
• Preferred Dividend Payments fell to $2.6 million in Q2 2025 per RNAC's latest filing, from $4.2 million in the prior quarter.
• Across five years, Preferred Dividend Payments topped out at $4.2 million in Q2 2024 and bottomed at $2.6 million in Q2 2025.